Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2002

View Archived Issues

IND submitted for nitroglycerin lingual spray

Positive pharmacokinetic results for buccal desmopressin

Tacrolimus for psoriasis scheduled for marketing within three to four years

YC-1 may be useful for treating erectile dysfunction

GenStar to develop delivery vectors for Centocor

Chugai discusses business plan for Roche alliance

Improved pharmacological profile reported for CHF-4227.01 in postmenopausal osteoporosis

Bazedoxifene compares favorably with other SERMs in ovariectomized rat model of bone loss

New SERM from Pfizer may set the standard for therapy of menopausal disorders

Truncated peptide analogues of SDF-1 designed with significant biological activity

Barcelona-based researchers take major step towards a cure for type 1 diabetes

Antisense ODN directed against the human androgen receptor inhibits prostate tumor growth

Antex updates progress of AP-158

BioAstin improves condition of patients with carpal tunnel syndrome

Encouraging early clinical results announced for GnRH antagonist

Onconase inhibits RNA viruses including HIV-1

HuMax-CD4 provides long-lasting effects in phase II psoriasis trial

Shire inlicenses mesalazine MMX technology for ulcerative colitis

Avanir seeks approval for docosanol 10% cream in Sweden

JTC-801 representative of a new class of analgesics

Initiation of phase II trial of SMART anti-gamma interferon antibody in Crohn's disease

New treatments for diabetes and related disorders claimed by AstraZeneca

Hungarian biotech company identifies new MDR modulators

Alpha1-adrenoceptor antagonists useful for urological disorders

Progesterone receptor modulators in the Bayer pipeline

Potent and selective alpha4 integrin inhibitors useful for inflammatory conditions

AstraZeneca presents new NOS inhibitors and therapeutic applications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...